IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases

Teymouri, M. and Pirro, M. and Fallarino, F. and Gargaro, M. and Sahebkar, A. (2018) IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. International Journal of Cancer, 143 (9). pp. 2105-2115.

[img] Text
IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases.pdf

Download (653kB)

Abstract

Cytokine members of the IL-12 family have attracted enormous attention in the last few years, with IL-35 being the one of the most attractive-suppressive cytokine. IL-35 is an important mediator of regulatory T cell function. Regulatory T cells play key roles in restoring immune homeostasis after facing challenges such as infection by specific pathogens. Moreover, a crucial role for regulatory T cell populations has been demonstrated in several physiological processes, including establishment of fetal–maternal tolerance, maintenance of self-tolerance and prevention of autoimmune diseases. However, a deleterious involvement of immune regulatory T cells has been documented in specific inhibition of immune responses against tumor cells, promotion of chronic infections and establishment of chronic inflammatory disorders. In this review, we attempt to shed light on the concept of immune-homoeostasis on the aforementioned issues, taking IL-35 as the hallmark of regulatory responses. The dilemma between immune-mediated cancer treatment and inflammation is discussed. Histopathological indications of chronic vs. acute infections are elaborated. Moreover, the evidence that IL-35 requires additional immune-regulatory cytokines, such as IL-10 and TGF-β, to induce effective and maximal anti-inflammatory effects suggest that immune-regulation requires multi-factorial analysis of many immune playmakers rather than a specific immune target. © 2018 UICC

Item Type: Article
Additional Information: Cited By :14 Export Date: 16 February 2020 CODEN: IJCNA Correspondence Address: Sahebkar, A.; Pharmaceutical Technology Institute, Biotechnology Research Center, Mashhad University of Medical SciencesIran; email: sahebkara@mums.ac.ir
Uncontrolled Keywords: autoimmunity IL-35 immune tolerance infection inflammation interleukin 10 interleukin 12 interleukin 23 interleukin 27 interleukin 35 transforming growth factor beta interleukin derivative interleukin-35, human adaptive immunity allergic disease autoimmune disease cancer growth CD4+ T lymphocyte CD8+ T lymphocyte cell expansion Chagas disease clinical indicator cytokine production hepatitis B histopathology human immunoregulation inflammatory disease innate immunity lymphocyte differentiation nonhuman pregnancy priority journal protein expression protein function Review Th1 cell Th17 cell Th2 cell tumor microenvironment upregulation chronic disease disease exacerbation immunological tolerance immunology neoplasm regulatory T lymphocyte Disease Progression Humans Interleukins Neoplasms T-Lymphocytes, Regulatory
Subjects: WC Communicable Diseases
QV pharmacology
QZ pathology-neoplasms-Genetics
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 27 Apr 2020 09:03
Last Modified: 27 Apr 2020 09:03
URI: http://eprints.mums.ac.ir/id/eprint/17561

Actions (login required)

View Item View Item